论文部分内容阅读
目的 研究CD4 4v6、C -erbB - 2基因在肺癌中的表达及临床意义。方法 采用免疫组化S -P法 ,检测CD4 4v6、C -erbB - 2基因蛋白在 116例肺癌中的表达。结果 在SCLC中 ,CD4 4v6、C -erbB - 2均不表达。在NSCLC中 ,CD4 4v6在鳞癌中的阳性表达率为 6 6 .7% ,腺癌为 36 .1% (P <0 .0 1)。C -erbB - 2在鳞癌中的阳性表达率为 4 7.8% ,腺癌为 6 6 .7% (P >0 .0 5 )。癌旁正常肺组织均未见CD4 4v6、C -erbB - 2的表达。CD4 4v6表达与NSCLC的肿瘤T分期、淋巴结转移、临床分期及生存率有关 (P <0 .0 5 ) ,而与病理分级无关 (P >0 .0 5 )。C -erbB - 2表达与NSCLC淋巴结转移、临床分期及生存率有关 (P <0 .0 5 ) ,而与肿瘤病理分级及肿瘤T分期无关 (P >0 .0 5 )。NSCLC中CD4 4v6与C -erbB - 2表达无相关性 (P >0 .0 5 )。结论 CD4 4v6、C -erbB - 2不仅可作为鉴别SCLC与NSCLC的参考指标 ,而且CD4 4v6、C -erbB - 2阳性表达的患者易发生淋巴结转移、病期较晚、预后差 ,故二者还可作为判断NSCLC预后的较可靠的指标。
Objective To study the expression and clinical significance of CD4 4v6 and C-erbB-2 genes in lung cancer. Methods Immunohistochemical S-P method was used to detect the expression of CD4 4v6 and C-erbB-2 gene protein in 116 cases of lung cancer. Results In SCLC, neither CD4 4v6 nor C-erbB-2 was expressed. In NSCLC, the positive expression rate of CD4 4v6 in squamous cell carcinoma was 66.7%, and adenocarcinoma was 36.1% (P < 0.01). The positive rate of C-erbB-2 in squamous cell carcinoma was 4 7.8%, and adenocarcinoma was 6 6.7% (P > 0.05). There was no expression of CD4 4v6 and C-erbB-2 in normal lung tissue adjacent to tumor. CD4 4v6 expression was associated with T stage, lymph node metastasis, clinical stage, and survival rate of NSCLC (P < 0.05), but not with pathological grade (P > 0.05). The expression of C-erbB-2 was related to lymph node metastasis, clinical stage and survival rate of NSCLC (P < 0.05), but not to tumor pathological grade and tumor T stage (P > 0.05). There was no correlation between CD4 4v6 and C-erbB-2 expression in NSCLC (P > 0.05). Conclusions CD4 4v6 and C-erbB-2 can be used not only as reference markers for identifying SCLC and NSCLC, but also patients with positive expression of CD4 4v6 and C-erbB-2 are prone to lymph node metastasis, late stage, and poor prognosis. Can be used as a more reliable indicator of the prognosis of NSCLC.